Lilly(Eli) & Company
NYSE: LLY
$921.49
+$6.45 (+0.7%)
Closing Price on September 20, 2024
LLY Articles
Thursday's top analyst upgrades, downgrades and initiations include Amazon, CenturyLink, Fitbit, Mobileye, Eli Lilly, Netflix and AT&T.
Published:
ThinkstockAs we get closer to second quarter earnings, many investors on Wall Street and Main Street are starting to concentrate on having stocks in portfolios that can not only hit or beat the...
Published:
Eli Lilly has made a big splash in the market over the past year. A key analyst sees this trend continuing despite some potential near-term headwinds.
Published:
Thursday's top analyst upgrades, downgrades and initiations include Bankrate, Eli Lilly, Embraer, Oracle and Southwest Airlines.
Published:
Wednesday's top analyst upgrades, downgrades and initiations include Arista Networks, Baidu, Chevron, Lexmark International, Occidental Petroleum and Salesforce.com.
Published:
24/7 Wall St. has put together a list of companies that have outperformed the market this past week.
Published:
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Published:
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair...
Published:
Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.
Published:
A recent research note from SunTrust Robinson Humphrey highlights some outstanding stocks that are out of favor.
Published:
In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising first-quarter earnings.
Published:
SunTrust Robinson Humphrey analysts expect the pharmaceutical industry to outperform in 2015, driven in part by a solid new product cycle and an attractive five-year growth rate.
Published:
A new research report from the technical team at RBC cites Bristol-Myers Squibb, Eli Lilly, Mylan and Perrigo as stocks that may continue to show sector leadership.
Published:
A new research report from SunTrust Robinson Humphrey is very positive on pharmaceuticals, and the analysts expect the sector to outperform this year.
Published:
One area that makes sense for growth investors is the large cap pharmaceuticals. Here are some the top pharmaceutical stocks to buy now according to Jefferies.
Published: